tiprankstipranks
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
PremiumThe FlyVerve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
2M ago
Verve Therapeutics Reports Q3 Progress and Financials
Premium
Company Announcements
Verve Therapeutics Reports Q3 Progress and Financials
2M ago
Verve Therapeutics reports Q3 EPS (59c), consensus (70c)
Premium
The Fly
Verve Therapeutics reports Q3 EPS (59c), consensus (70c)
2M ago
Verve Therapeutics price target lowered to $29 from $30 at Canaccord
PremiumThe FlyVerve Therapeutics price target lowered to $29 from $30 at Canaccord
5M ago
Verve Therapeutics reports Q2 EPS (59c), consensus (68c)
Premium
The Fly
Verve Therapeutics reports Q2 EPS (59c), consensus (68c)
5M ago
Verve Therapeutics Expands Board with Two New Members
Premium
Company Announcements
Verve Therapeutics Expands Board with Two New Members
7M ago
Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
PremiumCompany AnnouncementsVerve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
8M ago
Verve Therapeutics reports Q1 EPS (59c), consensus (71c)
Premium
The Fly
Verve Therapeutics reports Q1 EPS (59c), consensus (71c)
8M ago
Verve Therapeutics announces dosing of first patient in VERVE-102 trial
Premium
The Fly
Verve Therapeutics announces dosing of first patient in VERVE-102 trial
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100